Global COPD and Asthma Devices Market (Product Types and Geography) – Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 – 2020

Owing to all of the afore-mentioned factors the global COPD and Asthma devices’ market was valued at $25.3 billion in 2013. The global COPD and Asthma devices market is segmented based on product/device types – inhalers and nebulizers. There are three types of inhalers, namely Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs) and Soft Mist Inhalers (SMIs).

The COPD and Asthma hold the largest market share within the global respiratory diseases’ market. As estimated by Global Initiative for Asthma (GINA), approximately 300 million people suffer from Asthma globally. COPD was the 3rd leading cause for death with 3 million people in 2013. Variety of drug-delivery methods such as oral and parenteral delivery have been deployed for treatment of COPD and Asthma; however, the pulmonary drug delivery system is the most effective drug-delivery technology as compared to the other (stated) conventional methods. The pulmonary drug delivery system includes devices such as inhalers and nebulizers – that are types of COPD and Asthma devices. Owing to all of the afore-mentioned factors the global COPD and Asthma devices’ market was valued at $25.3 billion in 2013. The global COPD and Asthma devices market is segmented based on product/device types – inhalers and nebulizers. There are three types of inhalers, namely Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs) and Soft Mist Inhalers (SMIs). Currently, MDIs constitute to the largest market share of about 46% of the global COPD and Asthma devices market.

The DPIs is the fastest growing segment owing to the increase in the adoption rate of DPIs (as compared to other types of inhalers). The ability of DPIs to deliver small and large-sized drug molecules, as well as specialty engineered molecules render it to be the most preferred inhaler by the customers (doctors);therefore, contributing largely to the growth of the DPIs segment market.

The other product type segment, i.e. the Nebulizers, is the device wherein the liquid formulation of drug is dispensed with the help of compressed air. There are various types of nebulizers developed and supplied such as Compressor Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers. The nebulizers hold a largest market share in the Home Healthcare application, as the product design of nebulizers offers benefits to debilitated patients, geriatrics and children.

Geographically, the COPD and Asthma devices market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America holds the largest market share followed by Europe. Patent expiry of many brands (of inhalers) leads to increased development and supply of such devices by local market players in the Asia-Pacific market; also coupled with the increasing prevalence of the COPD and Asthma diseases in the Asia-Pacific region, the factors will render high market share for the Asia-Pacific region, by 2020. Some of the key market players included in the report are GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare, 3M Health Care, Allied Healthcare Products Inc., Sunovion Pharmaceuticals Inc., GF Healthcare Products, Smith Medicals, Lincare Holdings Inc., and Baxter International.

KEY BENEFITS

  • Competitor analysis of the global COPD and Asthma devices market helps to understand strategies adopted by various companies for growth
  • The projections in the report are made by analyzing the current market trends and future market potential for the period of 2013-2020 in terms of value
  • Pin-point analysis of geographic segments helps to identify opportunities for growth within the global COPD and Asthma Devices market
  • Comprehensive analysis of factors that drive and restrict growth of the COPD and Asthma devices market is provided. For example, rising prevalence of respiratory disorders would drive the COPD and Asthma devices market; however, environmental concerns are likely to be a restraint of the market
  • Market conditions of global COPD and Asthma devices across all geographic regions are comprehensively analyzed. Development of technologically advanced products such as ultrasonic nebulizers and other automated nebulizers are tracked.
  • Porter’s Five Forces model gives an in-depth analysis of the bargaining power of buyers and suppliers, threats of new entrants and substitutes and competition amongst the key market players

MARKET SEGMENTATION

  • The COPD and Asthma devices market is segmented based on product types and geography.

MARKET BY PRODUCT TYPE 

  • Inhalers
  • Drug powder inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers (SMIs)
  • Nebulizers
  • Compressor nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers

MARKET BY GEOGRAPHY 

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Others
  • Asia-Pacific
  • India
  • China
  • Japan
  • Australia
  • Others
  • LAMEA
  • Latin America
  • Middle east
  • Africa

Table of Content

CHAPTER 1 INTRODUCTION
1.1 Report Description
1.2 Reason for doing the study
1.3 Key Benefits
1.4 Key Market Segments
1.5 Key Audiences
1.6 Research Methodology
1.6.1 Secondary Research
1.6.2 Primary Research
1.6.3 Analyst tools and models

CHAPTER 2  EXECUTIVE SUMMARY 
2.1 CXO perspective
2.2 Market beyond what to expect by 2025 ($Million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Key Findings
3.2.1 Top Factors Impacting on global COPD and Asthma devices market
3.2.2 Top Investment Pockets of global COPD and Asthma devices market
3.2.3 Top winning strategies of global COPD and Asthma devices market
3.3 Government Regulations
3.4 Porter’s Five force Analysis
3.5 Value chain analysis
3.6 Clinical Trials
3.7 Patent Analysis
3.8 Market Share Analysis, 2013
3.9 Market Dynamics
3.9.1 Drivers
3.9.2 Restraints
3.9.3 Opportunities

CHAPTER 4 GLOBAL COPD AND ASTHMA DEVICES MARKET BY PRODUCT TYPE, 2013-2020, $MILLION
4.1 Inhalers
4.1.1 Drug powder inhalers (DPIs)
4.1.1.1 Key market trends
4.1.1.2 Key growth factors and opportunities
4.1.1.3 Market size and forecast
4.1.2 Metered Dose Inhalers (MDIs)
4.1.2.1 Key market trends
4.1.2.2 Key growth factors and opportunities
4.1.2.3 Market size and forecast
4.1.3 Soft Mist Inhalers (SMIs)
4.1.3.1 Key market trends
4.1.3.2 Key growth factors and opportunities
4.1.3.3 Market size and forecast
4.2 Nebulizers
4.2.1 Compressor Nebulizers
4.2.2 Ultrasonic Nebulizers
4.2.3 Mesh Nebulizers

CHAPTER 5 GLOBAL COPD AND ASTHMA DEVICES  MARKET BY GEOGRAPHY, 2013-2020, $MILLION
5.1 North America
5.1.1 Key market trends
5.1.2 Key growth factors and opportunities
5.1.3 Market size and forecast
5.1.4 United States
5.1.4.1 Market size and forecast
5.1.5 Canada
5.1.5.1 Market size and forecast
5.1.6 Mexico
5.1.6.1 Market size and forecast
5.1.7 Others
5.1.7.1 Market size and forecast
5.2 Europe
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 France
5.2.4.1 Market size and forecast
5.2.5 Germany
5.2.5.1 Market size and forecast
5.2.6 United Kingdom
5.2.6.1 Market size and forecast
5.2.7 Others
5.2.7.1 Market size and forecast
5.3 Asia-Pacific
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.3.4 India
5.3.4.1 Market size and forecast
5.3.5 China
5.3.5.1 Market size and forecast
5.3.6 Japan
5.3.6.1 Market size and forecast
5.3.7 Australia
5.3.7.1 Market size and forecast
5.3.8 Others
5.3.8.1 Market size and forecast
5.4 LAMEA
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Latin America
5.4.4.1 Market size and forecast
5.4.5 Middle East
6.4.5.1 Market size and forecast
5.4.6 Africa
5.4.6.1 Market size and forecast

CHAPTER 6  COMPANY PROFILES
6.1 GlaxoSmithKline Plc
6.1.1 Overview
6.1.2 Company snapshot
6.1.3 Financial performance
6.1.4 Operating segment
6.1.5 Strategic moves and developments
6.1.6 SWOT analysis
6.2 Novartis AG
6.2.1 Overview
6.2.2 Company snapshot
6.2.3 Financial performance
6.2.4 Operating segment
6.2.5 Strategic moves and developments
6.2.6 SWOT analysis
6.3 Merck & Co., Inc.
6.3.1 Overview
6.3.2 Company snapshot
6.3.3 Financial performance
6.3.4 Operating segment
6.3.5 Strategic moves and developments
6.3.6 SWOT analysis
6.4 Philips Healthcare
6.4.1 Overview
6.4.2 Company snapshot
6.4.3 Financial performance
6.4.4 Operating segment
6.4.5 Strategic moves and developments
6.4.6 SWOT analysis
6.5 AstraZeneca Plc
6.5.1 Overview
6.5.2 Company snapshot
6.5.3 Financial performance
6.5.4 Operating segment
6.5.5 Strategic moves and developments
6.5.6 SWOT analysis
6.6 3M Health Care
6.6.1 Overview
6.6.2 Company snapshot
6.6.3 Financial performance
6.6.4 Operating segment
6.6.5 Strategic moves and developments
6.6.6 SWOT analysis
6.7 Allied Healthcare Products Inc.
6.7.1 Overview
6.7.2 Company snapshot
6.7.3 Financial performance
6.7.4 Operating segment
6.7.5 Strategic moves and developments
6.7.6 SWOT analysis
6.8 GF Health Products Inc.
6.8.1 Overview
6.8.2 Company snapshot
6.8.3 Financial performance
6.8.4 Operating segment
6.8.5 Strategic moves and developments
6.8.6 SWOT analysis
6.9 Sunovion Pharmaceuticals Inc.
6.9.1 Overview
6.9.2 Company snapshot
6.9.3 Financial performance
6.9.4 Operating segment
6.9.5 Strategic moves and developments
6.9.6 SWOT analysis
6.10 Smith Medicals
6.10.1 Overview
6.10.2 Company snapshot
6.10.3 Financial performance
6.10.4 Operating segment
6.10.5 Strategic moves and developments
6.10.6 SWOT analysis
6.11 Lincare Holdings Inc.
6.11.1 Overview
6.11.2 Company snapshot
6.11.3 Financial performance
6.11.4 Operating segment
6.11.5 Strategic moves and developments
6.11.6 SWOT analysis
6.12 Baxter International
6.12.1 Overview
6.12.2 Company snapshot
6.12.3 Financial performance
6.12.4 Operating segment
6.12.5 Strategic moves and developments
6.12.6 SWOT analysis


List of Tablet

?TABLE. 1 TOP IMPACTING FACTOR, BASE CASE SCENARIO (2020-2025)
TABLE  2 TOP IMPACTING FACTOR OPTIMISTIC SCENARIO (2020-2025)
TABLE 3 TOP IMPACTING FACTOR CRITICAL SCENARIO (2020-2025)
TABLE 4 GLOBAL COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 5 GLOBAL COPD AND ASTHMA INHALERS MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 6 GLOBAL COPD AND ASTHMA INHALERS – DRY POWDER INHALERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 7 GLOBAL COPD AND ASTHMA INHALERS – METERED DOSE INHALERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 6 GLOBAL COPD AND ASTHMA INHALERS – SOFT MIST INHALERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 9 GLOBAL COPD AND ASTHMA NEBULIZERS MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 10 GLOBAL COPD AND ASTHMA NEBULIZERS – COMPRESSOR NEBULIZERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 11 GLOBAL COPD AND ASTHMA NEBULIZERS- ULTRASONIC NEBULIZERS
MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 12 GLOBAL COPD AND ASTHMA NEBULIZERS – MESH NEBULIZERS MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 13 GLOBAL COPD AND ASTHMA DEVICES MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 14 NORTH AMERICA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 15 UNITED STATES COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 16 CANADA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 17 MEXICO COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 18 OTHER NORTH AMERICA  COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 19 EUROPE COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 20 GERMANY COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 21 FRANCE COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 22 UNITED KINGDOM COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 23 OTHER EUROPE COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 24 ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 25 CHINA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 26 INDIA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 27 JAPAN COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 28 AUSTRALIA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 29 OTHER ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 30 LAMEA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 31 LATIN AMERICA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 32 MIDDLE EAST COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 33 AFRICA COPD AND ASTHMA DEVICES MARKET BY TYPES, 2013-2020, ($MILLION)
TABLE 34 GLAXOSMITHKLINE PLC BUSINESS SNAPSHOT
TABLE 35 GLAXOSMITHKLINE PLC OPERATING SEGMENTS
TABLE 36 NOVARTIS AG BUSINESS SNAPSHOT
TABLE 37 NOVARTIS AG OPERATING SEGMENTS
TABLE 38 MERCK AND CO BUSINESS SNAPSHOT
TABLE 39 MERCK AND CO OPERATING SEGMENTS
TABLE 40 ASTRAZENECA PLC BUSINESS SNAPSHOT
TABLE 41 ASTRAZENECA PLC OPERATING SEGMENTS
TABLE 42 PHILIPS HEALTHCARE BUSINESS SNAPSHOT
TABLE 43 PHILIPS HEALTHCARE OPERATING SEGMENTS
TABLE 44 3M HEALTH CARE BUSINESS SNAPSHOT
TABLE 45 3M HEALTH CARE OPERATING SEGMENTS
TABLE 46 ALLIED HEALTHCARE PRODUCTS INC BUSINESS SNAPSHOT
TABLE 47 ALLIED HEALTHCARE PRODUCTS INC OPERATING SEGMENTS
TABLE 48 SUNOVION PHARMACEUTICALS BUSINESS SNAPSHOT
TABLE 49 SUNOVION PHARMACEUTICALS OPERATING SEGMENTS
TABLE 50 GF HEALTH PRODUCTS BUSINESS SNAPSHOT
TABLE 51 GF HEALTH PRODUCTS OPERATING SEGMENTS
TABLE 52 SMITH MEDICALS BUSINESS SNAPSHOT
TABLE 53 SMITH MEDICALS OPERATING SEGMENTS
TABLE 54 LINCARE HOLDINGS INC BUSINESS SNAPSHOT
TABLE 55 LINCARE HOLDINGS INC OPERATING SEGMENTS
TABLE 56 BAXTER INTERNATIONAL BUSINESS SNAPSHOT
TABLE 57 BAXTER INTERNATIONAL OPERATING SEGMENTS


List Of Figure

?FIG. 1 TOP IMPACTING FACTOR, BASE CASE SCENAIRIO (2020-2025)
FIG. 2 TOP IMPACTING FACTOR OPTEMISTIC SCENAIRIO (2020-2025)
FIG. 3 TOP IMPACTING FACTOR CRITICAL SCENAIRIO (2020-2025)
FIG 4 TOP FACTORS IMPACTING GLOBAL COPD AND ASTHMA DEVICES MARKET, 2013
FIG. 5 TOP WINNING STRATEGY IN CLOBAL COPD AND ASTHMA DEVICES MARKET, 2010 TO 2014
FIG.6 TOP INVESTMENT POCKETS IN GLOBAL COPD AND ASTHMA DEVICES MARKETS (2013)
FIG. 7 PORTER FIVE FORCES ANALYSIS OF GLOBAL COPD AND ASTHMA DEVICES MARKETS
FIG. 8 VALUE CHAIN ANALYSIS OF GLOBAL COPD AND ASTHMA DEVICES MARKETS
FIG. 9 PATENT ANALYSIS IN GLOBAL COPD AND ASTHMA DEVICES MARKET, 2010-2014
FIG. 10 MARKET SHARE ANALYSIS OF COPD AND ASTHMA DEVICES MARKET (2013)
FIG. 11 RECENT DEVELOPMENTS OF GLOBAL COPD AND ASTHMA DEVICES MARKET (2010-2014)
FIG. 12GLAXOSMITHKLINE PLC SWOT ANALYSIS
FIG. 13 NOVARTIS AG SWOT ANALYSIS
FIG. 14 MERCK AND CO., INC SWOT ANALYSIS
FIG. 15 ASTRAZENECA PLC SWOT ANALYSIS
FIG. 16 PHILIPS HEALTHCARE SWOT ANALYSIS
FIG. 17 3M HEALTH CARE SWOT ANALYSIS
FIG. 18 ALLIED HEALTHCARE PRODUCTS INC SWOT ANALYSIS
FIG. 19 SUNOVION PHARMACEUTICALS INC SWOT ANALYSIS
FIG. 20 GF HEALTH PRODUCTS SWOT ANALYSIS
FIG. 21 SMITH MEDICALS SWOT ANALYSIS
FIG. 22 LINCARE HOLDINGS INC SWOT ANALYSIS
FIG. 23 BAXTER INTERNATIONAL SWOT ANALYSIS

Name: (required)

Email: (required)

Phone: (required)

Company: (required)

Designation: (required)

Country: (required)

How can we help you?:

Type the pieces of text below (required)
captcha



Name: (required)

Email: (required)

Phone: (required)

Company: (required)

Designation: (required)

Country: (required)

How can we help you?:

Type the pieces of text below (required)
captcha



Carl